Table 1.
Baseline characteristics of subjects who completed the 24-week, double blind, placebo controlled portion of the study.
| Placebo (n = 11) | Curcumin 2 gm/day (n = 9) | Curcumin 4 gm/day (n = 10) | ||
|---|---|---|---|---|
| Age in years | 70.2 (12.4) | 76.7 (5.6) | 75.3 (6.9) | P = 0.71 |
| Gender, number of women (%) | 6 (55%) | 6 (67%) | 7 (70%) | P = 0.74 |
| Years of education (S.D.) | 14.3 (2.5) | 16.7 (1.3) | 15.0 (2.7) | P = 0.08 |
| Number on AchE-I's (%) | 11 (100%) | 7 (78%) | 10 (100%) | P = 0.08 |
| Number on memantine (%) | 8 (73%) | 7 (78%) | 8 (80%) | P = 0.92 |
| MMSE (S.D., range) | 23.2 (2.3, 20-27) | 21.4 (3.2, 17-28) | 22.8 (3.4, 18-27) | P = 0.41 |
| ADAS-Cog score (S.D.) | 18.2 (4.9) | 20.9 (7.4) | 19.3 (3.4) | P = 0.64 |
| NPI total score (S.D.) | 8.5 (12.4) | 8.9 (9.6) | 11.7 (16.9) | P = 0.84 |
| ADCS-ADL score (S.D.) | 66.7 (3.6) (n = 10) | 60.3 (10.9) | 61.0 (8.4) | P = 0.18 |
Note that ADCS-ADL score was not available on one subject in the placebo arm. AchE-I, acetylcholinesterase inhibitor; ADAS-Cog, Alzheimer's Disease Assessment Scale - Cognitive Subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study - Activities of Daily Living; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; S.D., standard deviation.